Plain-English translation of NCT05864534 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating newly diagnosed glioblastoma (a serious type of brain cancer) by combining three things: a small implanted device that uses ultrasound waves, and two immune-boosting medications called and , plus a chemotherapy drug called . The ultrasound is designed to open a protective barrier around the brain and allow the medications to reach cancer cells more effectively. Researchers hope this combination will work better than standard treatment alone.
Glioblastoma is very difficult to treat because the brain has a protective barrier that blocks most medications from reaching tumors. This trial exists to test whether using ultrasound waves to temporarily open that barrier—combined with medications that boost the immune system—might help destroy cancer cells that standard treatments cannot reach.
You likely qualify if…
You likely don't qualify if…
You would first have a small device surgically implanted in your skull 1–5 weeks after completing radiation therapy. Then, starting 1–3 weeks after that surgery, you would visit the clinic every 3 weeks for about 6 months. At each visit, the device would deliver ultrasound waves to open the blood-brain barrier, and you would receive intravenous infusions of the medications. You would also have regular MRI scans and blood tests to monitor how the treatment is working and check for side effects. The first 6 patients in the trial will receive extra safety monitoring.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States